Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Harpagophytum Extract Ws 1531
2. Harpagoside-b
3. Ws 1531
4. Ws1531
1. 19210-12-9
2. E-harpagoside
3. 8kgs1dc5zu
4. Chebi:5625
5. [(1s,4as,5r,7s,7as)-4a,5-dihydroxy-7-methyl-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,5,6,7a-tetrahydrocyclopenta[c]pyran-7-yl] (e)-3-phenylprop-2-enoate
6. Smr001233395
7. Unii-8kgs1dc5zu
8. Harpaside
9. Einecs 242-881-6
10. Prestwick3_000988
11. Harpagoside [inci]
12. Bspbio_001055
13. Harpagoside [who-dd]
14. Mls002154086
15. Mls002473324
16. Schembl893387
17. Bpbio1_001161
18. Chembl516702
19. Megxp0_000469
20. Harpagoside, Analytical Standard
21. Acon0_000056
22. Acon1_000134
23. Dtxsid101032528
24. Hms2098e17
25. Hms2231n12
26. Hy-n0396
27. Zinc8214398
28. Mfcd00017415
29. S9171
30. Akos015896715
31. Ccg-269650
32. Lmpr0102070010
33. Ncgc00179325-01
34. Ncgc00179325-02
35. Ncgc00179325-04
36. Ac-34268
37. As-56071
38. Ab00513986
39. Cs-0008931
40. C09783
41. H10494
42. 210h129
43. A880338
44. Q-100231
45. Brd-k07996107-001-01-7
46. Brd-k07996107-001-03-3
47. Harpagoside, Primary Pharmaceutical Reference Standard
48. Q25099323
49. Harpagoside, European Pharmacopoeia (ep) Reference Standard
50. (1s,4as,5r,7s,7as)-4a,5-dihydroxy-7-methyl-1-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-7-yl Cinnamate
51. (1s,4as,5r,7s,7as)-4a,5-dihydroxy-7-methyl-1-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-7-yl Cinnamate
52. (1s-(1alpha,4aalpha,5alpha,7alpha(e),7aalpha))-1,4a,5,6,7,7a-hexahydro-4a,5-dihydroxy-7-methyl-7-((allyl-1-oxo-3-phenyl)oxy)cyclopenta(c)pyran-1-yl-beta-d-glucopyranoside
53. .beta.-d-glucopyranoside, (1s,4as,5r,7s,7as)-1,4a,5,6,7,7a-hexahydro-4a,5-dihydroxy-7-methyl-7-(((2e)-1-oxo-3-phenyl-2-propenyl)oxy)cyclopenta(c)pyran-1-yl
54. Ncgc00179325-04_c24h30o11_(1s,4as,5r,7s,7as)-1-(beta-d-glucopyranosyloxy)-4a,5-dihydroxy-7-methyl-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-7-yl (2e)-3-phenylacrylate
| Molecular Weight | 494.5 g/mol |
|---|---|
| Molecular Formula | C24H30O11 |
| XLogP3 | -0.6 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 7 |
| Exact Mass | 494.17881177 g/mol |
| Monoisotopic Mass | 494.17881177 g/mol |
| Topological Polar Surface Area | 175 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 811 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Harpagoside manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Harpagoside, including repackagers and relabelers. The FDA regulates Harpagoside manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Harpagoside API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Harpagoside supplier is an individual or a company that provides Harpagoside active pharmaceutical ingredient (API) or Harpagoside finished formulations upon request. The Harpagoside suppliers may include Harpagoside API manufacturers, exporters, distributors and traders.
click here to find a list of Harpagoside suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Harpagoside CEP of the European Pharmacopoeia monograph is often referred to as a Harpagoside Certificate of Suitability (COS). The purpose of a Harpagoside CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Harpagoside EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Harpagoside to their clients by showing that a Harpagoside CEP has been issued for it. The manufacturer submits a Harpagoside CEP (COS) as part of the market authorization procedure, and it takes on the role of a Harpagoside CEP holder for the record. Additionally, the data presented in the Harpagoside CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Harpagoside DMF.
A Harpagoside CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Harpagoside CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Harpagoside suppliers with CEP (COS) on PharmaCompass.
Harpagoside Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Harpagoside GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Harpagoside GMP manufacturer or Harpagoside GMP API supplier for your needs.
A Harpagoside CoA (Certificate of Analysis) is a formal document that attests to Harpagoside's compliance with Harpagoside specifications and serves as a tool for batch-level quality control.
Harpagoside CoA mostly includes findings from lab analyses of a specific batch. For each Harpagoside CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Harpagoside may be tested according to a variety of international standards, such as European Pharmacopoeia (Harpagoside EP), Harpagoside JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Harpagoside USP).
LOOKING FOR A SUPPLIER?
